Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific administrative event: a revaluation of the cash element of a notional investment held within the US Retirement Savings Plan, which resulted in an increase in the notional allocation of American Depositary Shares (ADSs).
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Transaction Date: The notional allocation increase occurred on May 11, 2012.
- Transaction Price: $45.62 per ADS.
- Involved Parties: Dr. M M Slaoui (Director) and Dr. K Slaoui (Connected Person).
- Transaction Details: Dr. K Slaoui received a notional allocation of 5 ADSs; Dr. M M Slaoui had no change in allocation.
- Plan Context: The transaction relates to the US Retirement Savings Plan, which holds notional investments in GSK ADSs.